LGVN
Longeveron Inc. NASDAQ Listed Feb 12, 2021$0.86
Mkt Cap $20.0M
52w Low $0.47
29.0% of range
52w High $1.80
50d MA $0.91
200d MA $0.80
P/E (TTM)
-0.7x
EV/EBITDA
-0.2x
P/B
2.6x
Debt/Equity
0.1x
ROE
-400.1%
P/FCF
-0.5x
RSI (14)
—
ATR (14)
—
Beta
-0.19
50d MA
$0.91
200d MA
$0.80
Avg Volume
5.7M
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
1951 NW 7th Avenue · Miami, FL 33136 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.42 | -0.22 | +47.6% | 0.96 | -13.8% | +1.7% | +13.7% | -11.7% | -2.7% | -6.3% | — |
| Nov 4, 2025 | AMC | -0.26 | -0.39 | -50.0% | 0.80 | +0.0% | -4.8% | +1.0% | -4.3% | +0.6% | -3.3% | — |
| Aug 13, 2025 | AMC | -0.35 | -0.33 | +5.7% | 0.86 | +0.0% | -12.2% | +0.6% | +6.4% | +2.3% | -3.4% | — |
| May 8, 2025 | AMC | -0.34 | -0.34 | +0.0% | 1.49 | -4.7% | -10.1% | +9.7% | -2.0% | -6.2% | +3.7% | — |
| Feb 28, 2025 | AMC | -0.36 | -2.50 | -594.4% | 1.52 | +3.9% | -9.2% | -3.6% | +5.3% | +2.9% | +4.9% | — |
| Nov 12, 2024 | AMC | -0.53 | -0.34 | +35.8% | 2.30 | -5.2% | -7.8% | -1.9% | -4.8% | -2.5% | -4.1% | — |
| Aug 14, 2024 | AMC | -1.03 | -1.83 | -77.7% | 2.61 | -12.3% | -5.7% | -4.5% | +0.4% | -5.1% | +14.3% | — |
| May 14, 2024 | AMC | -2.01 | -1.61 | +19.9% | 1.39 | +2.2% | -3.6% | -3.7% | -0.8% | -3.1% | -4.0% | — |
| Feb 27, 2024 | AMC | -2.10 | -2.50 | -19.0% | 5.79 | +0.0% | -6.0% | -1.8% | +1.1% | -5.4% | +3.1% | — |
| Nov 10, 2023 | AMC | -2.40 | -2.80 | -16.7% | 18.20 | +4.4% | -1.1% | -2.8% | +9.7% | -5.2% | +4.4% | — |
| Aug 11, 2023 | AMC | -2.60 | -2.70 | -3.8% | 32.70 | -2.8% | -7.0% | -3.6% | -2.4% | -2.7% | +0.3% | — |
| May 12, 2023 | AMC | -1.90 | -2.20 | -15.8% | 33.00 | -0.9% | -1.8% | -8.0% | +2.0% | +4.3% | +4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 | Roth Capital | Maintains | Buy → Buy | — | $0.76 | $0.78 | +3.3% | +0.6% | +6.4% | +2.3% | -3.4% | +0.0% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.77 | +0.6% | +5.1% | +0.5% | -4.3% | -3.4% | -1.2% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.58 | +3.9% | -9.2% | -3.6% | +5.3% | +2.9% | +4.9% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.89 | $1.90 | +0.5% | +3.7% | +2.0% | +3.0% | -0.5% | +0.5% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.03 | $2.03 | +0.0% | +6.4% | +4.2% | -4.4% | +2.3% | +0.0% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.01 | -2.4% | +5.3% | -0.5% | -8.8% | +5.1% | -1.4% |
| Aug 27 | Maxim Group | Maintains | Buy → Buy | — | $2.41 | $2.32 | -3.7% | -5.4% | -7.0% | -1.4% | -2.4% | +1.0% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.29 | -12.3% | -5.7% | -4.5% | +0.4% | -5.1% | +14.3% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.27 | $3.22 | -1.5% | -4.3% | -2.9% | -4.9% | -8.3% | +9.1% |
| Jul 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.44 | $4.07 | +18.3% | +0.9% | -5.8% | -4.3% | -2.9% | -4.9% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.29 | $1.31 | +1.6% | -0.8% | -3.1% | -4.0% | -2.5% | -3.4% |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.75 | $1.75 | +0.0% | -3.4% | +1.2% | +1.8% | +4.0% | -3.3% |
| May 16 | EF Hutton | Maintains | Buy → Buy | — | $32.40 | $32.20 | -0.6% | -8.0% | +2.0% | +4.3% | +4.1% | -0.9% |
| May 9 | EF Hutton | Maintains | Buy → Buy | — | $31.60 | $35.20 | +11.4% | +26.6% | -14.8% | +1.2% | -4.3% | -1.8% |
| Mar 27 | EF Hutton | Maintains | Buy → Buy | — | $27.70 | $28.00 | +1.1% | -2.2% | -1.1% | +0.0% | -0.7% | +0.4% |
| Jan 10 | EF Hutton | Maintains | Buy → Buy | — | $33.00 | $32.60 | -1.2% | +1.5% | +3.0% | +0.6% | +6.6% | +8.1% |
| Mar 24 | Maxim Group | Maintains | Buy → Buy | — | $65.20 | $67.50 | +3.5% | +9.2% | -5.3% | -1.0% | +4.3% | -3.4% |
| Jan 5 | EF Hutton | Maintains | Buy → Buy | — | $116.00 | $143.70 | +23.9% | +2.2% | -15.7% | -3.1% | -1.3% | +6.1% |
No insider trades available.
8-K · 8.01
!! High
Longeveron Inc. -- 8-K 8.01: Material Event / Announcement
May 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
LGVN's executive received significant RSU compensation vesting over three years, signaling management confidence in long-term strategy but potentially diluting existing shareholders through future equity issuance.
Apr 10
8-K
Unknown — 8-K Filing
LGVN received a Nasdaq compliance notice but retains listing status; investors should monitor whether management successfully executes a reverse split or other remedial measures to avoid delisting within the required timeframe.
Mar 25
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
LGVN's forward-looking statements disclaimer suggests management is cautioning investors about execution risks and uncertain business conditions, warranting scrutiny of their strategic guidance and near-term performance targets.
Mar 24
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
LGVN amended its preferred stock terms, linking the second closing of a financing to Phase 2b HLHS trial success, indicating investor capital remains contingent on clinical efficacy and creating stock dilution risk if milestone is missed.
Mar 12
8-K · 5.02
!!! Very High
Longeveron Inc. -- 8-K 5.02: Executive Change
Longeveron Inc. replaced Executive Chairman Richard Kender with director Roger Hajjar, signaling leadership transition that investors should monitor for strategic direction changes.
Mar 9
8-K · 5.02
!!! Very High
Longeveron Inc. -- 8-K 5.02: Executive Change
Longeveron appointed Stephen H. Willard as Chief Executive Officer, signaling new leadership that may reshape company strategy and investor confidence in the regenerative medicine firm.
Feb 13
Data updated apr 25, 2026 7:05pm
· Source: massive.com